LNP Technologies

Lipid Nanoparticle Technology

As the Lipid Technology segment of the Croda Pharma business, Avanti is primarily focused on developing innovative lipid-based products to address specific medical challenges that are not resolved by current technology or drug products.

Curious about our innovative lipids and their ability to fuel your drug delivery research?

For over 30 years, Avanti has been working with the pharmaceutical and diagnostic industry to provide solutions that save or improve lives. We were integrally involved in the development of liposomal-based drug delivery systems and over the past decade, we have concentrated on developing lipid components used in Lipid Nanoparticle (LNP) delivery technology to solve the stability and delivery issues associated with mRNA-based vaccines and therapeutics.

LNPs are lipid-based drug delivery systems that carry nucleic acid material. These systems primarily rely on four lipid components: a PEG lipid, amino (cationic) lipid, structural lipid, and cholesterol.

The cationic lipids are used to sequester the genetic material through a charge-charge interaction. This is encapsulated by the structural lipid and functionalized on the exterior with PEG lipids. Genetic material is highly susceptible to RNAse activity but the LNP protects the genetic material from degradation. The LNP also allows the genetic material to access the cell and, once inside, be released. This allows the cellular machinery to translate the delivered genetic material into a cellular response.

When conducting LNP formulation research there are many important factors to consider including size and shape, surface charge, hydrophobicity, and surface functionalization. Avanti offers a wide variety of cGMP manufactured lipids that will allow you to perfectly tailor your drug delivery systems. As always, these lipids are manufactured to meet the highest purity standards ensuring targeted, controlled, and extended-release of active pharmaceutical ingredients, increasing efficacy and safety.

If you have a lipid-based drug delivery problem that needs to be solved, reach out to us! We can help you with:

Nobody surpasses Avanti’s quality or dedication to finding solutions for lipid-based problems. We have supplied lipids for commercial drug product manufacturing for over 30 years and we are here to help you, too.


Cullis PR, Hope MJ. Lipid Nanoparticle Systems for Enabling Gene Therapies. Mol Ther. 2017 Jul 5;25(7):1467-1475. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498813/

Jayaraman et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo.

Angew Chem Int Ed Engl. 2012 Aug 20;51(34):8529-33. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3470698/

Wan C, Allen TM, Cullis PR. Lipid nanoparticle delivery systems for siRNA-based therapeutics. Drug Deliv Transl Res. 2014 Feb;4(1):74-83. https://link.springer.com/article/10.1007/s13346-013-0161-z

LNP Systems PPT: Download